{"database":"GPMDB","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":15,"searchCount":3},"additional":{"omics_type":["Other"],"submitter":["Vineet Sangar, et al."],"instrument_platform":["Instrument"],"disease":["Not Available"],"brenda_tissue":["Not available"],"species":["Homo_sapiens_viruses, Human"],"submitter_mail":["nprice@systemsbiology.org"],"publication":["24997998"],"submitter_affiliation":["Institute for Systems Biology, USA"],"model":["http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028696","http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028752","http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028766","http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028723","http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028737","http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028709","http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028781"],"cell_type":["Not available"],"repository":["GPMDB"],"pubmed_abstract":["Glioblastoma multiforme is a highly invasive and aggressive brain tumor with an invariably poor prognosis. The overexpression of epidermal growth factor receptor (EGFR) is a primary influencer of invasion and proliferation in tumor cells and the constitutively active EGFRvIII mutant, found in 30-65% of Glioblastoma multiforme, confers more aggressive invasion. To better understand how EGFR contributes to tumor aggressiveness, we investigated the effect of EGFR on the secreted levels of 65 rationally selected proteins involved in invasion. We employed selected reaction monitoring targeted mass spectrometry using stable isotope labeled internal peptide standards to quantity proteins in the secretome from five GBM (U87) isogenic cell lines in which EGFR, EGFRvIII, and/or PTEN were expressed. Our results show that cell lines with EGFR overexpression and constitutive EGFRvIII expression differ remarkably in the expression profiles for both secreted and intracellular signaling proteins, and alterations in EGFR signaling result in reproducible changes in concentrations of secreted proteins. Furthermore, the EGFRvIII-expressing mutant cell line secretes the majority of the selected invasion-promoting proteins at higher levels than other cell lines tested. Additionally, the intracellular and extracellular protein measurements indicate elevated oxidative stress in the EGFRvIII-expressing cell line. In conclusion, the results of our study demonstrate that EGFR signaling has a significant effect on the levels of secreted invasion-promoting proteins, likely contributing to the aggressiveness of Glioblastoma multiforme. Further characterization of these proteins may provide candidates for new therapeutic strategies and targets as well as biomarkers for this aggressive disease."],"pubmed_title":["Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells."],"pubmed_authors":["Sangar Vineet V,Funk Cory C CC,Kusebauch Ulrike U,Campbell David S DS,Moritz Robert L RL,Price Nathan D ND,","Sangar Vineet V, Funk Cory C CC, Kusebauch Ulrike U, Campbell David S DS, Moritz Robert L RL, Price Nathan D ND"],"name_synonyms":["receptor tyrosine-protein kinase erbB-1, proto-oncogene c-ErbB-1, Wa5, TGF-alpha receptor activity, ERBB, Proteins, number, Gene, Errb1, [M]Glioblastoma NOS (morphologic abnormality), mENA, Giant Cell, Grade IV, Astrocytomas, presence, PIG61, polypeptide, count in organism, Glioblastoma (morphologic abnormality), Grade IV Astrocytic Neoplasm, Spongioblastoma Multiforme, count, epidermal growth factor receptor activity, wa2, AI552599, Protein, proteomic analysis, Gene Products, EGF receptor activity, NOS, Cell., Giant Cell Glioblastomas, Glioblastoma, Grade IV Astrocytic Tumor, EGFR, Glioblastomas, GBM, ERBB1, proteins, [M]Glioblastoma NOS, GBM - Glioblastoma multiforme, wa-2, Giant Cell Glioblastoma, Astrocytoma, Protein Gene Products, Gene Proteins, Glioblastoma Multiforme, no ICD-O subtype, Grade IV Astrocytomas, Errp, no ICD-O subtype (morphologic abnormality), Erbb, 9030024J15Rik, transforming growth factor-alpha receptor activity, GLM - Glioblastoma multiforme, Grade IV Astrocytoma, quantitative, Glioblastoma NOS (morphologic abnormality), GBM (Glioblastoma), HER1, NISBD2, presence or absence in organism"],"description_synonyms":["receptor tyrosine-protein kinase erbB-1, U87 cell, criteria, proto-oncogene c-ErbB-1, AI461847, GLM2, mol, SRML1, U-87 MG cell, Neoplasms, Gene, Errb1, U87, Spectrum Analyses, mENA, Tumor, guidelines, Grade IV, Astrocytomas, U-87 cell, NEOPL, PIG61, peptide, MHAM, Glioblastoma (morphologic abnormality), Spongioblastoma Multiforme, AI552599, AI463227, Gene Products, Mass, U-87-MG cell, Line, EGF receptor activity, Pgi, TEP1, Analysis, Gpi-1, Giant Cell Glioblastomas, Mass Spectroscopy, Mass Spectrum Analysis, MRM, Analyses, Gpi-1r, Nlk, cell, Gpi-1s, Phi, Gpi-1t, cell line cell, tumour, proteins, [M]Glioblastoma NOS, EGFRvIII, Giant Cell Glioblastoma, U-87MG cell, cell line, Astrocytoma, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), Glioblastoma Multiforme, no ICD-O subtype (morphologic abnormality), B430203M17Rik, 9030024J15Rik, Grade IV Astrocytoma, glomerular capillary basement membrane, Neoplastic Growth, NISBD2, SPS1, Tumors, U87MG cell, Gpi, data, Wa5, TGF-alpha receptor activity, ERBB, Proteins, PAPT, Cell Lines, cell_line, [M]Glioblastoma NOS (morphologic abnormality), MF, Giant Cell, SPDSY, Amf, Spectrum Analysis, Cell, tumours, Multiple Reaction Monitoring, Spectroscopy, polypeptide, Grade IV Astrocytic Neoplasm, Experiment, mOC-X, epidermal growth factor receptor activity, wa2, PTEN1, CWS1, Protein, NOS, NK|GPI, glomerular filtration membrane, Mass Spectrum Analyses, NK, Lines, Mass Spectrum, Org, ORG, Mmac, Glioblastoma, 10q23del, Grade IV Astrocytic Tumor, U87-MG cell, MMAC1, EGFR, SRM, Spectrometry, Glioblastomas, GBM, Gpi1-r, Gpi1-s, ERBB1, GBM - Glioblastoma multiforme, wa-2, A130070J02Rik, Gpi1-t, Protein Gene Products, Gene Proteins, DEC, no ICD-O subtype, Grade IV Astrocytomas, 2310035O07Rik., Errp, Erbb, transforming growth factor-alpha receptor activity, GLM - Glioblastoma multiforme, Glioblastoma NOS (morphologic abnormality), BZS, Bglap-rs1, NEOPLASMS BENIGN, Neoplasia, GBM (Glioblastoma), HER1, Gpi1s, 2310035O07Rik"],"pubmed_title_synonyms":["receptor tyrosine-protein kinase erbB-1, proto-oncogene c-ErbB-1, Wa5, TGF-alpha receptor activity, ERBB, Proteins, number, Gene, Errb1, [M]Glioblastoma NOS (morphologic abnormality), mENA, Giant Cell, Grade IV, Astrocytomas, presence, PIG61, polypeptide, count in organism, Glioblastoma (morphologic abnormality), Grade IV Astrocytic Neoplasm, Spongioblastoma Multiforme, count, epidermal growth factor receptor activity, wa2, AI552599, Protein, proteomic analysis, Gene Products, EGF receptor activity, NOS, Cell., Giant Cell Glioblastomas, Glioblastoma, Grade IV Astrocytic Tumor, EGFR, Glioblastomas, GBM, ERBB1, proteins, [M]Glioblastoma NOS, GBM - Glioblastoma multiforme, wa-2, Giant Cell Glioblastoma, Astrocytoma, Protein Gene Products, Gene Proteins, Glioblastoma Multiforme, no ICD-O subtype, Grade IV Astrocytomas, Errp, no ICD-O subtype (morphologic abnormality), Erbb, 9030024J15Rik, transforming growth factor-alpha receptor activity, GLM - Glioblastoma multiforme, Grade IV Astrocytoma, quantitative, Glioblastoma NOS (morphologic abnormality), GBM (Glioblastoma), HER1, NISBD2, presence or absence in organism"],"pubmed_abstract_synonyms":["U87 cell, Viral Marker, Biological Markers, nucleocytoplasm, Surrogate Endpoints, Laboratory, Brain Neoplasms, Biochemical, Endpoint, Errb1, U87, Tumor, Serum, Astrocytomas, PIG61, peptide, Glioblastoma (morphologic abnormality), Laboratory Markers, INTRACRANIAL NEOPL, Oxidative, Biological, AI552599, U-87-MG cell, Line, BRAIN NEOPL PRIMARY MALIGNANT, TEP1, Analysis, NEOPL BRAIN PRIMARY, Mass Spectrum Analysis, human disease, Prognoses, Analyses, BRAIN NEOPL BENIGN, Brain Malignant Neoplasms, Primary Brain Tumors, cell line cell, [M]Glioblastoma NOS, Brain Tumor, proteins, elevated, Giant Cell Glioblastoma, cell line, Astrocytoma, Oxidative Stresses, Immune, Markers, Brain Neoplasm, Primary Malignant Brain Tumors, no ICD-O subtype (morphologic abnormality), signaling process, Viral Markers, Recurrent Brain Tumor, Concentrations, NEOPL BRAIN BENIGN, 9030024J15Rik, Homo sapiens disease, NISBD2, single organism signaling, Tumors, U87MG cell, Intracranial Neoplasm, Viral, Malignant Brain Neoplasms, Surrogate Endpoint, Brain Benign Neoplasm, Wa5, Malignant Primary Brain Neoplasms, Biochemical Markers, BRAIN NEOPL MALIGNANT, Primary Brain Neoplasm, Giant Cell, NEOPL BRAIN, Biologic Marker, Spectrum Analysis, tumours, results, Primary Brain Tumor, Multiple Reaction Monitoring, Spectroscopy, BRAIN NEOPL PRIMARY, Benign, Brain Benign Neoplasms, wa2, PTEN1, Marker, Diseases., Brain Malignant Neoplasm, Malignant Primary Brain Tumors, NOS, NEOPL BRAIN MALIGNANT, internal to cell, Malignant Brain Neoplasm, Lines, Primary Malignant, Glioblastoma, Factors, End Points, Cancer of the Brain, U87-MG cell, Prognostic, EGFR, MMAC1, Spectrometry, GBM, Benign Neoplasms, GBM - Glioblastoma multiforme, Immunologic, Laboratory Marker, Malignant Neoplasms, Intracranial, Grade IV Astrocytomas, Biochemical Marker, GLM - Glioblastoma multiforme, Glioblastoma NOS (morphologic abnormality), BZS, GBM (Glioblastoma), Prognostic Factor, 2310035O07Rik, Brain, receptor tyrosine-protein kinase erbB-1, Brain Tumors, biological signaling, Primary Malignant Brain Neoplasms, criteria, BRAIN NEOPL MALIGNANT PRIMARY, proto-oncogene c-ErbB-1, GLM2, Clinical Markers, U-87 MG cell, Clinical Marker, Neoplasms, Cancer of Brain, Primary Brain Neoplasms, Benign Neoplasm, MALIGNANT PRIMARY BRAIN NEOPL, Gene, Prognostic Factors, Spectrum Analyses, Grade IV, mENA, guidelines, Malignant, U-87 cell, NEOPL, Stresses, Surrogate End Points, MHAM, Surrogate Markers, Spongioblastoma Multiforme, Recurrent Brain Tumors, Recurrent, AI463227, Gene Products, Mass, EGF receptor activity, Giant Cell Glioblastomas, Mass Spectroscopy, protoplasm, study, Clinical, MRM, protoplast, Biological Marker, tumour, EGFRvIII, U-87MG cell, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), Glioblastoma Multiforme, Immunologic Markers, PRIMARY BRAIN NEOPL, Concentration, B430203M17Rik, Grade IV Astrocytoma, glomerular capillary basement membrane, high elevation, Immunologic Marker, Neoplastic Growth, Biologic, NEOPL INTRACRANIAL, Cancer, Malignant Neoplasm, TGF-alpha receptor activity, ERBB, Benign Brain Neoplasms, Proteins, Serum Markers, BENIGN NEOPL BRAIN, Cell Lines, End Point, BRAIN NEOPL, cell_line, [M]Glioblastoma NOS (morphologic abnormality), Primary, Factor, MALIGNANT NEOPL BRAIN, Cell, Immune Marker, polypeptide, Grade IV Astrocytic Neoplasm, epidermal growth factor receptor activity, Surrogate End Point, CWS1, Protein, Neoplasm, Brain Cancers, glomerular filtration membrane, Mass Spectrum Analyses, Biologic Markers, Intracranial Neoplasms, Mass Spectrum, Serum Marker, Mmac, 10q23del, Surrogate, Grade IV Astrocytic Tumor, SRM, Endpoints, Glioblastomas, ERBB1, Cancers, wa-2, A130070J02Rik, Brain Cancer, Surrogate Marker, signalling, Protein Gene Products, Gene Proteins, extracellular, DEC, no ICD-O subtype, signalling process, PRIMARY MALIGNANT BRAIN NEOPL, Errp, Erbb, Stress, Benign Brain Neoplasm, transforming growth factor-alpha receptor activity, Attentions, NEOPLASMS BENIGN, Neoplasia, HER1, Immune Markers"],"view_count":["15"],"citation_count":["0"],"search_count":["3"],"full_dataset_link":["http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210028781"],"search_domains":["dbgap_ncbi~0","patentfamilies~0","rfam~0","merops~0","complex-portal~0","uniprot~0","wormbaseparasite~0","embl-covid19~0","reactome~0","emdb~0","wgs_masters~0","ebiweb_resources~0","opentargets_genetics~0","biomodels_all~0","ipd-mhc~0","ebiweb_teams~0","taxonomy~0","genome_assembly~0","sc-experiments~0","ebiweb_people~0","enzymeportal_enzymes~0","ipd-nhkir~0","cellosaurus~0","pdbe~0","chebi~0","patentproteins~0","interpro7~0","uniref~0","chembl~0","pdbekb~0","gpcrdb~0","hgnc~0","sc-genes~0","intact~0","rhea~0","ebiweb_training~0","alphafold~0","imgt-hla~0","patentnucleotides~0","ensemblroot~0","eva_studies~0","non-coding~0","europepmc~0","pubmed~1","identifiers_registry~0","pdbechem~0","hpa-covid19~0","eva-variants-covid19~0","biosamples~0","gwas_catalog~0","biotools~0","tls_masters~0","mesh~0","coding~0","sra~0","opentargets~0","efo~0","embl-pathogen~0","project~0","human_diseases~0","geo_datasets~0","embl~0","treefam~0","uniparc~0","ols~0","dgva~0","intenz~0","go~0","tsa_masters~0","biosamples-covid19~0","ebiweb_corporate~0","omim~0","lrg~0","earlycause-molecular-sequences~0","ipd-kir~0","empiar~0","rnacentral~0","orcid_data_claims~0","gpmdb~2","lineage-covid19~0","metagenomics~0","pfam~0","varsite~0"],"citation_count_scaled":["0.0"],"reanalysis_count_scaled":["0.0"],"view_count_scaled":["0.0046267735965453425"],"download_count_scaled":["0.0"],"reanalysis_count":["0"],"normalized_connections":["1.0"],"additional_accession":[]},"is_claimable":false,"name":"Quantitative proteomic analysis reveals effects of EGFR on invasion-promoting proteins secreted by glioblastoma cells.","description":"Data from PeptideAtlas, [[http://www.peptideatlas.org/PASS/PASS00455 PASS00455]]. Experiment: PTEN+EGFR_1, file: folder summary. Published as part of Mol Cell Proteomics. 2014 Jul 5  . From the Abstract: {{i}} ... To better understand how EGFR contributes to tumor aggressiveness, we investigated the effect of EGFR on the secreted levels of 65 rationally selected proteins involved in invasion. We employed selected reaction monitoring (SRM) targeted mass spectrometry using stable isotope labeled internal peptide standards to quantity proteins in the secretome from five GBM (U87) isogenic cell lines in which EGFR, EGFRvIII and/or PTEN were expressed. {{/i}} ","dates":{"submission":"2014-07-21"},"accession":"GPM11210028781","cross_references":{"pubmed":["24997998"]}}